Premium
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up
Author(s) -
Ahlstrand Erik,
Samuelsson Jan,
Lindgren Marie,
Pettersson Helna,
Liljeholm Maria,
RavnLandtblom Anna,
Scheding Stefan,
Andréasson Björn
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13373
Subject(s) - medicine , polycythemia vera , essential thrombocythemia , incidence (geometry) , complication , life expectancy , cohort , vascular disease , surgery , risk factor , population , physics , environmental health , optics
Objective To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV). Methods Nested case‐control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls. Results Incidence of vascular complications was 2.0 and 3.4 events per 100 patient‐years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti‐thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls. Conclusions The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti‐thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.